Biotech News
Related news
OCSOculis2026-10-19 06:00 EST
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
OCSOculis2026-10-29 09:39 EST
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
OKYOOKYO Pharma2026-09-09 11:00 EST
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
LCTXLineage Cell Therapeutics2026-11-12 21:03 EST
Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease
RHHBYRoche Holdings AG2026-10-21 12:00 EST
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
OCGNOcugen2026-09-01 11:02 EST
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
OKYOOKYO Pharma2026-07-20 11:00 EST
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
KPRXKiora Pharmaceuticals2026-10-29 11:00 EST
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
PRQRProQR Therapeutics2026-09-09 12:00 EST
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-11-16 07:00 EST
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
OCSOculis2026-11-13 21:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-11-09 07:00 EST
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
OCSOculis2026-11-03 21:05 EST
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
OCSOculis2026-11-02 07:00 EST
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Stock data
- Close
- 7.44 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
